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Introduction {#sec1}
============

Progress in human pluripotent stem cell (hPSC) research has the potential to revolutionize regenerative medicine. Functional hPSC progenies may either fuel advanced *in vitro* assays for better drug development or replenish the loss of functional cells in diseased organs.

Given the high incidence of cardiac disorders, there have been substantial efforts in investigating cardiomyogenic differentiation of hPSCs. Stages of differentiation include early mesendoderm priming ([@bib30]), specification of cardiac progenitors ([@bib58]), and directed differentiation into cardiomyocyte (CM) subtypes such as ventricular-, atrial- and nodal-like phenotypes ([@bib15], [@bib52]). Process specification was also accompanied by revealing more lineage-specific surface markers facilitating monitoring of differentiation stages and process optimization (reviewed in [@bib57]).

The field has also progressed from using recombinant factors toward chemical compounds for directing CM induction. These protocols typically aim at mimicking the biphasic pattern of WNT pathway upregulation and subsequent attenuation known from early heart development ([@bib21], [@bib38], [@bib60], [@bib61]). Notably, chemical WNT pathway stimulators (particularly the GSK3 inhibitor CHIR99021 \[CHIR\]) or suppressors (including IWP2, IWR1, and Wnt-C59) have also been applied to specify other mesendodermal lineages including hepatocytes ([@bib55]) and skeletal muscle cells ([@bib54]). This highlights process complexity due to the multiple spatiotemporally dependent roles of the WNT pathway in development. Moreover, we have recently demonstrated that, in response to CHIR stimulation, a complex pattern of paracrine factors, whose feedback-controlled concentration depends on the applied cell density, substantially modulates early primitive streak (PS)-like priming ([@bib20], [@bib30]). Thus, in addition to the well-studied impact of the CHIR dose, the cell density and the exact process timing have a dominant impact on hPSC differentiation.

Cell production in suspension culture by the differentiation of matrix-free hPSC aggregates is more compatible with process upscaling. It facilitates transition to stirred tank bioreactors favored for process control and optimization for conventional mammalian cell lines in the biotech industry. We and others demonstrated feasibility of suspension culture for both hPSC expansion ([@bib1], [@bib35]) and lineage differentiation, including successful CM, endothelial cell, and macrophage production ([@bib2], [@bib10], [@bib19], [@bib31], [@bib48]). However, whereas two-dimensional (2D) culture is restricted in their complexity, the number of process variables increases in 3D suspension culture. Besides the overall cell density, spherical aggregates (3D) increase in size over time (4D), thus constantly changing the physical and physiological parameters of the culture.

Multidimensional process parameters in combination with the known hPSC line-dependent properties often result into interexperimental variability. We have reported, for example, the average induction of ∼80% CMs in stirred suspension, but noted process variability ranging from \<60% to \>90% CM content ([@bib31]).

We thus performed systematic modifications of process parameters in this study by applying several culture platforms and numerous hPSC lines. By focusing on the critical early steps particularly on hPSC aggregation and the timing of chemical WNT modulation, a more robust and efficient protocol was developed. This includes the systematic usage of chemically defined media compatible with large-scale cell production and transition to good manufacturing practice standards. Applying molecular cell analysis in response to process modifications a novel surface marker, ROR1, is revealed which, in combination with CD13, is superior for predictive monitoring of cardiac mesoderm formation.

Results {#sec2}
=======

WNT Pathway Inhibition Improves Priming toward Cardiac Mesoderm {#sec2.1}
---------------------------------------------------------------

After kick-starting cardiac differentiation by 24 h of CHIR supplementation, WNT pathway attenuation is typically initiated after a 48- to 72-h gap ([@bib31], [@bib38]). In contrast to CHIR treatment, temporal patterning of WNT inhibition was less systematically investigated, particularly in suspension culture. We thus compared the effect of early (days 1--3) with that of the commonly applied late (days 3--5) supplementation of WNT inhibitors (schematic in [Figure 1](#fig1){ref-type="fig"}A). Flow cytometry (FC)-based endpoint analysis for CM-specific markers including cardiac troponin T (cTNT), sarcomeric actinin (SA), and myosin heavy chain (MHC) on day 10 revealed only low CM induction of ∼15%--18% (HES3) and \<1.5% (HSC-iPS2), respectively ([Figures 1](#fig1){ref-type="fig"}B and [S1](#mmc1){ref-type="supplementary-material"}A), when the WNT antagonist IWP2 was added on day 3. In contrast, starting inhibition on day 1 (i.e., immediately after CHIR removal) resulted in \>75% CM content for both cell lines and all markers tested ([Figure 1](#fig1){ref-type="fig"}B). This was confirmed by qRT-PCR ([Figure S1](#mmc1){ref-type="supplementary-material"}D) and immune cytology-based analysis of suspension-derived, plated cells ([Figure 1](#fig1){ref-type="fig"}C).Figure 1Timed WNT Pathway Inhibition Primes Mesendoderm toward Cardiac Mesoderm(A) Differentiation schematic. Aggregates generated in 12-well plates were transferred to agitated Erlenmeyer flasks 1 day prior (−1) to differentiation induction by CHIR (0); WNT inhibition was performed on day 1 or day 3 by IWP2.(B) CM content (%) measured by FC on day 10 following WNT inhibition on day 1 (![](fx2.gif)) and day 3 (![](fx3.gif)) for cardiac troponin T (cTNT), sarcomeric actinin (SA), and myosin heavy chain (MHC). 5 and 4 independent experiments were performed for hESCs and HSC_iPS2 cells, respectively. p \< 0.001.(C) IF staining of plated cells (day 14 + 4) for structural cardiac markers SA, TITIN, cTNT, and β-MHC. Scale bars, 100 μm.(D) PCA (σ/σ~max~ = 0.184) of microarray analysis shows clustering of samples over time and a distinct cell line-dependent pattern for IWP2 treatment. Two independent experiments were performed for each cell line.(E) Time course of selected cardiac/presomitic mesoderm markers. n = 4 independent experiments based on microarray signal intensities.Error bars represent SEM. See also [Figure S1](#mmc1){ref-type="supplementary-material"}.

Global gene expression analysis was conducted on day 0, day 1, and day 3 using HES3 (bright color code in [Figure 1](#fig1){ref-type="fig"}D) and HSC_iPS2 cells treated with (green dots) or without (gray dots) IWP2 on days 1--3 ([Figure 1](#fig1){ref-type="fig"}D). Principal component analysis showed expected clustering of day-0, -1, and -3 samples ([Figures 1](#fig1){ref-type="fig"}D and [S1](#mmc1){ref-type="supplementary-material"}C). Notably, day-3 samples receiving no IWP2 (gray) appeared more distant to day 1 along the PC1 axis compared with IWP2-treated cells (green). This indicates that the (differentiation-induced) changes were less pronounced when IWP2 was supplemented, suggesting containment of differentiation progression by the inhibitor.

Interestingly, early WNT pathway inhibition appears to be essential to direct certain hPSC lines such as HSC_iPS2 toward the cardiomyogenic lineage, whereas the HES3 line seems to be less sensitive to external WNT inhibitors, in line with previous work ([@bib31]).

Gene ontology (GO) analysis of \>10-fold regulated gene sets revealed that IWP2 treatment induced significant upregulation of genes related to the GO terms heart development and morphogenesis, while downregulated genes were associated with development and morphogenesis of the skeletal system, cartilage, bone, and cartilage, all resembling paraxial mesoderm derivatives ([Figure S1](#mmc1){ref-type="supplementary-material"}B).

Patterning into cardiac versus presumptive presomitic mesoderm was confirmed by targeted heatmap analysis for associated GO terms, including osteoblast, skeletal muscle, mesenchyme, somite, and limb development. Remarkably, day-3 analysis of IWP-treated cells showed robust upregulation of key cardiac progenitor markers including *ISL1*, *GATA4*, *MEF2C*, *NXK2-6* ([@bib6]), *FZD4* ([@bib65]), and *FOXC1/2*, as well as *TTN* and *TNNI1* ([Figure 1](#fig1){ref-type="fig"}E). Conversely, markers described to inhibit cardiac mesoderm but to promote presomitic specification including *CDX1/2* and *MSX1/2* ([@bib22], [@bib44]) were significantly upregulated in the absence of early IWP2 treatment (confirmed for CDX2 by FC; [Figure S1](#mmc1){ref-type="supplementary-material"}E).

ROR1 Distinguishes Cardiac from Paraxial Mesoderm {#sec2.2}
-------------------------------------------------

Multiple surface markers were reported to identify cardiac mesoderm during hPSC differentiation. We evaluated expression of these markers in our 3D system regarding their ability to discriminate cardiac versus presomitic mesoderm on day 3 of differentiation on gene and protein levels. Most established markers showed only marginal or low induction (*KDR*, *CXCR4*, and *GYPA*), while others were upregulated (*PDGFRA*, *NCAM*, *CD13*, and *ROR2*) but failed to discriminate between the two lineages ([Figures 2](#fig2){ref-type="fig"}A, 2B, [S2](#mmc1){ref-type="supplementary-material"}A, and S2B). Interestingly, ROR1, in contrast to the structurally related protein ROR2 (60% homology in protein sequence), depicted significantly higher levels in cardiac compared with presomitic mesoderm ([Figures 2](#fig2){ref-type="fig"}A, 2B, [S2](#mmc1){ref-type="supplementary-material"}A, and S2C). Studies in mice reported *Ror2* expression throughout the entire PS ([@bib43]) while recent data indicate distinct *Ror1* expression in the anterior-to-mid PS only ([@bib51]) ([Figure 2](#fig2){ref-type="fig"}C) suggesting a distinct role of *Ror1* during mesendodermal patterning (note that T delineates the PS area of the epiblast of the gastrulating embryo; [Figure 2](#fig2){ref-type="fig"}C). Likewise, proteome data from human fetal tissues revealed prominent expression of *ROR1* but not other established surface markers in the developing heart ([@bib33]) ([Figure 2](#fig2){ref-type="fig"}D). Indeed, in contrast to the combination of CD13^+^/ROR2^+^ (r = 0.73), combining analysis of CD13^+^/ROR1^+^ by FC on day 3 and corresponding cardiomyocyte content on day 10 showed a more significant correlation (r = 0.9) ([Figures 2](#fig2){ref-type="fig"}E, 2F, and [S2](#mmc1){ref-type="supplementary-material"}B), with CD13^+^ serving as panmesoderm marker to exclude the potential presence of pluripotent cells that also express ROR1 but lack CD13 ([Figure S2](#mmc1){ref-type="supplementary-material"}A).Figure 2ROR1 Serves as Predictive Surrogate Marker for Cardiomyocyte Formation(A) Volcano plot comparing cardiac and presomitic mesoderm on day 3 of differentiation. Key genes for each condition are highlighted in respective colors, either grouped in categories (![](fx2.gif), ![](fx4.gif), ![](fx5.gif), ![](fx6.gif)) or individually (![](fx7.gif), ![](fx8.gif)). Note the detection of *ROR1* (![](fx6.gif)) in the cardiac mesoderm by three independent probes and the minor difference for established surface markers (![](fx5.gif)), n = 4 independent experiments.(B) Representative FC histograms for ROR2, CD13, and ROR1 on day 3 with (![](fx2.gif)) and without (![](fx3.gif)) IWP2 treatment on day 1.(C) Gene expression in the gastrulating mouse embryo ([@bib51]) indicates *Ror1* expression (right panel) in the anterior-to-mid PS region whereby T expression (left panel) increases toward the posterior PS.(D) Pattern of mesodermal surface markers in human fetal tissues ([@bib33]) indicates high *ROR1* levels in the heart.(E) Representative FC on day 3 for NCAM/EpCAM, CD13/ROR2 and CD13/ROR1 with/without addition of IWP2 on day 1 and corresponding CM content (cTNT, SA, MHC) on day 10.(F) Correlation of ROR1^+^/CD13^+^ on day 3 and respective CM content on day 10 based on three different cell lines; each dot represents an independent biological repeat. r denotes Pearson\'s correlation coefficient. Dotted lines denote 95% confidence interval.See also [Figure S2](#mmc1){ref-type="supplementary-material"}.

Taken together, these data revealed ROR1 as a marker for cardiac mesoderm which, in combination with CD13, enables early prediction of cardiac differentiation efficiency.

Cell-Line-Independent Cardiomyogenesis in Chemically Defined Media {#sec2.3}
------------------------------------------------------------------

Considering upscaling of CM production for clinical translation, the development of cost-efficient xeno-free processes is essential. Based on successful hPSC expansion and maintenance of pluripotency in stirred suspension culture in chemically defined E8 ([@bib9], [@bib35]), it was applied to replace mTeSR used previously ([@bib41], [@bib49], [@bib56]) and in this work ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). For CM differentiation the chemically defined medium CDM3, recently established in 2D, was utilized ([@bib7]). Based on reports demonstrating the importance of the preculture strategy ([@bib10], [@bib19], [@bib31]), we combined modified timing of aggregate generation in E8 with the improved WNT modulation described above. Aggregates were formed in E8 in stirred tank bioreactors for either 2 or 4 days before transition to either CDM3 or RPMI/B27 (routinely used previously by [@bib31], [@bib38]), and for differentiation in rotated Erlenmeyer flasks (schematic in [Figure 3](#fig3){ref-type="fig"}A).Figure 3Day-2 Aggregates Derived in E8 Show Superior CM Formation in Chemically Defined Differentiation Medium(A) Experimental scheme for optimizing expansion timing before differentiation. Microscopy of day 2/day 4 aggregates.(B) Diameter assessment: evaluating \>100 aggregates on day 2/day 4 from three independent runs. p \< 0.0001.(C) Cell density on day 2/day 4 of three independent runs in duplicates, respectively. p = 0.0019.(D) Representative pH/DO curves of preculture.(E and F) The impact of CHIR concentration and preculture duration. FC on day 10 revealed higher content of GFP^+^ CMs applying day-2 precultures in (E) RPMI/B27 (n = 3 independent experiments, preculture duration p =0.0262 and 5 versus 7.5 μM CHIR p = 0.0439) or (F) CDM3 (n = 3 independent experiments, 7.5 versus 70 μM CHIR p = 0.0095).Error bars represent SEM. See also [Figure S3](#mmc1){ref-type="supplementary-material"}.

An increase in average aggregate diameter from 128.5 ± 49.60 μm on day 2 to 203.2 ± 79.3 μm on day 4 was observed ([Figure 3](#fig3){ref-type="fig"}B and picture inset in [Figure 3](#fig3){ref-type="fig"}A) while the cell density increased by ∼4-fold (0.49 ± 0.07 × 10^6^ and 2.2 ± 0.4 × 10^6^ cells/mL, respectively; [Figure 3](#fig3){ref-type="fig"}C). Dissolved oxygen (DO) and pH ([Figure 3](#fig3){ref-type="fig"}D) values were substantially lower for day 4 than for day 2, demonstrating that, in addition to the mere change in aggregate diameters (suggested to impact on differentiation; [@bib10], [@bib19]), numerous other physical and physiological parameters that may impact on differentiation vary as well.

Cells\' sensitivity to WNT pathway stimulation may also depend on the applied media. The CHIR concentration previously optimized to 7.5 μM in mTeSR/RPMI/B27 was thus reinvestigated ([@bib31]). Twenty-four hours of CHIR treatment at 5, 7.5, or 10 μM, respectively was immediately replaced by IWP2 for 48 h (days 1--3), and NKX2.5-eGFP expression was monitored as CM surrogate marker on day 10. For day-2 aggregates in RPMI/B27, 31.6% ± 11.8% of NKX2.5-eGFP^+^ cells were observed at 5 μM CHIR and even lower values were found for 7.5 μM and 10 μM CHIR, respectively ([Figure 3](#fig3){ref-type="fig"}E). For day-4 aggregates, the amount of GFP-expressing cells was also highest at 5 μM CHIR but the overall values were lower compared with day-2 aggregates ([Figure 3](#fig3){ref-type="fig"}E). Differentiation in CDM3 substantially improved NKX2.5-eGFP expression and was most robust combining E8-derived day-2 aggregates with 7.5 μM CHIR (83.8% ± 4.4%; [Figure 3](#fig3){ref-type="fig"}F). Day-2 aggregates outperformed day-4 cells over the entire CHIR range tested ([Figure 3](#fig3){ref-type="fig"}F).

This chemically defined protocol (equivalent to schematic in [Figure 3](#fig3){ref-type="fig"}A) was tested with several lines (HES3-NKX2.5, HSC_iPS2, and Phoenix) with day-2 aggregates following differentiation in flasks at 5 μM and 7.5 μM CHIR.

In contrast to HES3-NKX2.5, 5 μM CHIR was optimal for HSC_iPS2 and Phoenix, inducing 91% and 93.7% ± 3.6% CMs, respectively ([Figure 4](#fig4){ref-type="fig"}A). CHIR at 7.5 μM also resulted in substantially lower cell yield during subsequent differentiation ([Figures 4](#fig4){ref-type="fig"}B, [S3](#mmc1){ref-type="supplementary-material"}A, and S3B), eventually preventing endpoint analysis of HSC_iPS2 progenies. On the other hand, at 5 μM CHIR treatment, robust CM yields were observed for all cell lines tested ([Figure 4](#fig4){ref-type="fig"}B) whereby HES3-NKX2.5 were, again, less sensitive to the applied CHIR dose. Taken together, these data revealed that 5 μM CHIR is most appropriate for our chemically defined cardiac differentiation protocol.Figure 4Robust Differentiation in Chemically Defined Conditions across Multiple hPSC Lines(A and B) CM content (A) and respective cell numbers (B) on day 10 using bioreactor-derived aggregates from day-2 precultures of three cell lines differentiated in Erlenmeyer flasks in two or three independent experiments per cell line. (A) hESCs p = 0.1972, Phoenix cells p = 0.0575. (B) hESCs p = 0.8835, Pheonix cells p = 0.0067.(C) Robustness of the chemically defined differentiation protocol was confirmed by FC for three markers with \>70% CM found for seven cell lines tested in agitated 6-well plates in 2--5 independent experiments: hES3, bMHC_iPS, SFC840: n = 2; H9, CBiPS2, HDFiPS: n = 3; Phoenix: n = 5.(D) Comparison of IWP2 versus Wnt-C59 added after 24 h of 5 μM CHIR treatment in three independent experiments revealed similar efficiencies in 6-well plates on day 10 for Phoenix.Error bars represent SEM.

Additional human embryonic stem cell (hESC) and human iPSC (hiPSC) lines were assessed in a broadly available 6-well low-attachment platform revealing \>70% CM induction across the seven cell lines tested ([Figure 4](#fig4){ref-type="fig"}C), supporting the general cell-line- and culture platform-independent utility of our protocol. Moreover, comparing the WNT pathway inhibitors IWP2 with Wnt-C59 using Phoenix showed comparable differentiation efficiencies ([Figure 4](#fig4){ref-type="fig"}D).

Process Upscaling in Stirred Tank Bioreactors Enables High Cell Yield at \>90% CM Purity and Confirms Utility of CD13^+^/ROR1^+^ for Early Process Monitoring {#sec2.4}
-------------------------------------------------------------------------------------------------------------------------------------------------------------

Next, process upscaling in stirred tank bioreactors was performed, firstly in 150-mL (DASbox) and subsequently in up to 500-mL culture scale in a larger system (Bioblock). Applying the protocol in [Figure 5](#fig5){ref-type="fig"}A the cell density was adjusted to 0.5 × 10^6^ cells/mL before induction of differentiation to consider the impact of the bulk cell density and interprocess reproducibility ([@bib30]).Figure 5Process Upscaling in Stirred Tank Bioreactors Confirms Utility of CD13^+^/ROR1^+^ for Early Process Monitoring and Enables \>90% CM Induction(A) Scheme for differentiation in bioreactors and microscopic assessment of aggregates over time. Scale bars, 200 μm.(B) Growth kinetics in DASbox (n = 3 independent experiments) and the Bioblock system (n = 3 independent experiments). Error bars represent SEM.(C) Cardiac differentiation efficiency assessed by FC on day 10 for cTNT, SA, and MHC revealed \>90% purity in DASbox and ∼90% in Bioblock (n = 3 independent experiments). Error bars represent SEM.(D) Correlation of ROR1^+^/CD13^+^ on day 3 and respective CM content on day 10 of Phoenix in specific differentiation conditions resulting from upscale experiments. r denotes Pearson\'s correlation coefficient (n = 28 in seven independent experiments). Dotted line denotes 95% confidence interval.See also [Figure S4](#mmc1){ref-type="supplementary-material"}.

Growth kinetics revealed that the cell density peaked at \>1.5 × 10^6^ cells/mL on days 3--5 but declined thereafter, resulting in 1 ± 0.1 × 10^6^ total cells/mL on day 10 corresponding to 0.93 ± 0.1 × 10^6^ CMs/mL ([Figures 5](#fig5){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}B), thus yielding ∼130 × 10^6^ CMs per run in 150-mL scale.

On day 10, FC revealed a CM content of 93.5% ± 5.0%, 94,13% ± 2.8%, and 92.9% ± 3.64% for cTNT, MHC, and SA, respectively ([Figures 5](#fig5){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}A), demonstrating high process efficiency and reproducibility.

This endpoint analysis for CM markers was correlated to CD13^+^/ROR1^+^ on day 3 for a large number of experiments across the entire optimization phase, including preliminary conditions leading to low CM contents ([Figure 5](#fig5){ref-type="fig"}D). The observed correlation coefficient of r = 0.63 may not seem ideal but the following must be considered: (1) the biological variance inherent to such complex biological systems, in particular when correlating two time points being 7 days apart; and (2) the transient nature of the CD13^+^/ROR1^+^ expression whereby slight variations in process timing and analysis may substantially impact on this correlation. With this in mind, the plot in [Figure 5](#fig5){ref-type="fig"}D highlights that the presence of low, i.e., ∼20%--40% of CD13^+^/ROR1^+^ cells, on day 3 is a strong hint for low CM content, typically \<30% on day 10. In contrast, measurement of ∼60%--80% of CD13^+^/ROR1^+^ cells on day 3 typically resulted in 80%--98% CMs. As exemplarily depicted by inset pictures in the schematic ([Figure 5](#fig5){ref-type="fig"}A), the average cell aggregate diameter changed along bioreactor-based processes, rising from 112.8 ± 34.5 μm (day 0) to 214.5 ± 66.8 μm (day 10; [Figure S4](#mmc1){ref-type="supplementary-material"}D). Moreover, online monitoring of pH and DO revealed typical "zigzag" curves between individual medium changes ([Figure S4](#mmc1){ref-type="supplementary-material"}C). After day 3, the pH drop pattern was flatter in line with both decreasing cell numbers and the expected switch from a highly glycolytic metabolism established for the pluripotent state ([@bib12], [@bib45]) toward more oxidative phosphorylation (and thus reduced lactate production) in differentiating cells. This was confirmed by glucose/lactate assessment ([Figure S4](#mmc1){ref-type="supplementary-material"}E) for specific yield coefficient (Y) calculation, which was highest during the first days of differentiation and dropped strongly between days 2 and 5 ([Figure S4](#mmc1){ref-type="supplementary-material"}F).

We next performed a proof of concept for up to 3-fold process upscaling, i.e., from 150- toward 500-mL scale in a larger stirred tank reactor system (Bioblock) revealing high similarity for key parameters including growth kinetics, cell yields, and CM content, whereas a somewhat smaller mean aggregate diameter was observed at a larger scale ([Figure 5](#fig5){ref-type="fig"}F). The green bars in [Figure 5](#fig5){ref-type="fig"}C show that 89.13% ± 7.8%, 90.53% ± 6.7%, and 92.03% ± 4.4% of cTnT-, SA-, and MHC-expressing CMs, respectively, were observed on day 10. The cell density was 1.05 ± 0.19 × 10^6^ cells/mL (green line in [Figure 5](#fig5){ref-type="fig"}B). Together these data demonstrate platform- and process-scale-independent robustness.

Qualitative Analysis Reveals High Purity of Functional Ventricular Cardiomyocytes {#sec2.5}
---------------------------------------------------------------------------------

Assessing CMs' electrophysiological properties revealed 70 out of 73 action potentials (APs) with long plateau phase and steep phase-3 repolarization (physiological APs found at 37°C; [Figures 6](#fig6){ref-type="fig"}A, 6B, [S5](#mmc1){ref-type="supplementary-material"}A, and S5B), reflecting a ventricular-like phenotype with only three deviating APs noted in three independent differentiations ([Figures 6](#fig6){ref-type="fig"}A, 6B, [S5](#mmc1){ref-type="supplementary-material"}A, and S5C--S5E).Figure 6Characterization of CMs Generated by Chemically Defined Conditions(A and B) Electrophysiology: (A) representative APs indicating ventricular-like CMs recorded at room temperature (∼22°C) or ∼37°C. Spontaneous APs (upper) compared with evoked APs (lower) of the same cells, elicited by short stimuli from resting potentials of −80 mV; dotted lines: 0 mV. CM phenotype distribution: (B) in three independent differentiations of Phoenix, 3 out of 73 messured cells deviated from the ventricular-like AP pattern.(C--E) Single CM analysis: (C) systolic/diastolic calcium ratio at 0.5-/1-Hz stimulation; colors (![](fx8.gif),![](fx9.gif),![](fx10.gif),![](fx5.gif)) indicate four independent experiments (n = 57--71). (D) Time to peak of twitch contractions and half relaxation time at 0.5/1 Hz; four independent experiments, n = 74--93. Error bars denote median ± IQR. (E) Isoproterenol-induced upregulation of beating frequency (n = 5 in one experiment).(F--I) BCT analysis from two independent CM batches. (F) Tetramethylrhodamine methyl ester (TMRM) stain illustrates homogeneous CM distribution on day 7/day 21 of tissue formation. Scale bars, 1 mm. (G--I) Mechanical and electrophysiological properties of BCTs measured on day 21 (n = 10). (G) Example of spontaneous contraction pattern and (H) statistical analysis. (I) Force of spontaneous and paced contractions recorded over increasing preload.Error bars represent SEM. See also [Figures S5](#mmc1){ref-type="supplementary-material"} and [S6](#mmc1){ref-type="supplementary-material"}.

For intracellular calcium transients and unloaded twitch contraction recordings ([Figures 6](#fig6){ref-type="fig"}C and 6D), plated CMs were electrically stimulated ([@bib46]). The averaged diastolic calcium ratio at 0.5 Hz ([Figure 6](#fig6){ref-type="fig"}C) was 0.8 ± 0.15 and thus higher than 0.6 ± 0.1 previously found in hESC-CMs ([@bib46], [@bib63]), indicating a possibly lower activity of sarcoplasmic/endoplasmic calcium reticulum ATPase and Na^+^/Ca^2+^ exchanger in hiPSC-CMs in this study. This may be due to the shorter maturation time in culture (i.e., days 14--19 here versus day 35 in [@bib63]). At both electrical stimulation frequencies, systolic calcium ratios ([Figure 6](#fig6){ref-type="fig"}C) were higher compared with ([@bib63]) but the amplitude of calcium release (calculated as systolic peak/diastolic ratio) at 0.5 Hz was only slightly elevated (0.26 ± 0.18 versus 0.25 ± 0.1 in [@bib63]). Time to peak and half relaxation times ([Figure 6](#fig6){ref-type="fig"}D) of twitch contractions were similar to historical data ([@bib63]).

Notably, only 22% of all measured CMs were spontaneously contracting in the pacing-free interval of the acquisition protocol ([Figure S6](#mmc1){ref-type="supplementary-material"}F). This is ∼16% less than previously noted in hESC-CMs using the same analysis ([@bib63]), indicating that (without applying explicit maturation) we here derived CMs exhibiting a less contractile, more ventricular-like phenotype, a property of working myocardium.

Moreover, prolonged cultivation of CM aggregates in 3D resulted in progressively increasing expressions of ventricular myosin light chain 2 (MLC2, [Figures S6](#mmc1){ref-type="supplementary-material"}I and S6J) as indicated for prolonged cultivation of seeded CMs in 2D ([@bib7], [@bib38]).

Upon electrically evoked and spontaneous twitch contractions ([Figures 6](#fig6){ref-type="fig"}E and [S6](#mmc1){ref-type="supplementary-material"}C--S6E), isoproterenol slightly increased the contraction amplitude and marked shortening of time to peak and half relaxation times (expected positive inotropic and lusitropic effects, [Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E), and a significant increase of the beating frequency of spontaneously contracting CMs from 48.8 ± 3.26 to 68.4 ± 4.4 beats/min (expected positive chronotropic adrenergic effects; [Figures 6](#fig6){ref-type="fig"}E and [S6](#mmc1){ref-type="supplementary-material"}C). Moreover, endothelin-1 treatment for 24 h induced a typical increase in cell surface area of plated CMs ([@bib8]; [Figures S6](#mmc1){ref-type="supplementary-material"}A and S6B).

Finally, our resulting CMs were used for bioartificial cardiac tissue (BCT) generation ([@bib31], [@bib32]). After 21 days of cultivation, tissues displayed homogeneous distribution of aligned CMs and synchronized spontaneous beating at 62.8 ± 4.7 beats/min and contraction-relaxation times (t~C80%~) of 146.1 ± 6.0 and 181.8 ± 8.1 ms, respectively ([Figures 6](#fig6){ref-type="fig"}F--6I, [S6](#mmc1){ref-type="supplementary-material"}G, and S6H). In response to increased preload, both spontaneous and electrically paced forces increased significantly to 1.82 ± 0.04 and 1.80 ± 0.04 mN, respectively ([Figure 6](#fig6){ref-type="fig"}I). We also observed frequency-dependent acceleration of relaxation: compared with the initial relaxation time at 1 Hz, t~R80%~ was reduced by 28% or 51% at 2 Hz or 3 Hz, respectively ([Figures S6](#mmc1){ref-type="supplementary-material"}G and S6H).

Together, this highlights the typical physiological and mechanical properties of our hPSC-CMs indicating pronounced ventricular-like features.

Discussion {#sec3}
==========

Directed cardiac differentiation has been continuously improved over the past decade, progressing toward simpler, more robust, and scalable conditions ([@bib31], [@bib38], [@bib64]). In this study we introduce an integrated, chemically defined differentiation platform enabling the production of human cardiomyocytes in 3D aggregate culture suitable for upscaling in controlled stirred tank bioreactors.

Previous studies demonstrated a substantial impact of preculture conditions ([@bib31]) at the pluripotent hPSC aggregate stage ([@bib31]) and the early differentiation phase ([@bib18], [@bib30], [@bib44]) on cardiomyogenesis. Culture conditions were revealed that do support an accelerated differentiation progression including efficient PS formation and mesoderm induction, but ultimately failed to direct efficient cardiomyogenesis ([@bib31], [@bib30], [@bib36], [@bib44]).

We hypothesized here that, despite thoroughly directing hPSC priming toward precardiac mesoderm (i.e., by controlling cell aggregation and preculture timing, cell density adaptation ahead of differentiation, exact CHIR dosing, and incubation timing), the "48-h gap" of external WNT pathway control (which is inherent to the previous differentiation protocol, i.e., between CHIR deprivation after 24 h and before IWP addition at 72 h) is prone to perturbing lineage identity. Such perturbation is likely promoted by the complex paracrine environment and multiple signaling pathway activity in hPSCs downstream of CHIR addition ([@bib20], [@bib30]) and may lead to both a more broad induction of PS-like cell identities and less controlled progression to (posterior) mesoderm fates, i.e., paraxial mesoderm progenies.

We thus considered recent findings on mesoderm specification ([@bib40]) to more stringently control hPSC priming to a defined transition point of lateral mesoderm specification (by meticulously defined preculture and CHIR treatment). This is followed by efficient transition of the entire progenitor population toward cardiac mesoderm (rather than undesired branching toward, e.g., limb bud mesoderm; [@bib40]) by immediate chemical control of WNT pathway inhibition. The success of this immediate CHIR-to-IWP transition strategy is reflected in early gene expression data revealing suppression of CDX2 and MSX1, established inhibitors of cardiac mesoderm formation ([@bib44], [@bib53]).

Opposing the gene expression patterns specific to cardiac mesoderm (resulting from immediate IWP addition on day 1) versus presomitic mesoderm (achieved by the lack of IWP before day 3) allowed us to evaluate several known cardiac/mesodermal progenitor markers including KDR, PDGFRα, SSEA1, NCAM, ROR2, and CD13 ([@bib4], [@bib17], [@bib28], [@bib37], [@bib47], [@bib64], [@bib65]) regarding their suitability for early process monitoring and eventually predicting functional CM formation at later stages. Interestingly, none of the established markers was well suited to discriminate early cardiac from presomitic mesoderm. Instead, we identified ROR1 in combination with CD13 (to exclude presence of ROR1-expressing undifferentiated cells; see [Figure S2](#mmc1){ref-type="supplementary-material"}A) as being more informative in distinguishing between cardiac and presomitic mesoderm. This marker combination on day 3 was indeed more prognostic for indicating CM content on day 10, as demonstrated for several hPSC lines and culture platforms ([Figures 2](#fig2){ref-type="fig"}F and [5](#fig5){ref-type="fig"}D).

ROR1 and ROR2 are part of a WNT5A-ROR-DVL pathway in limb development, where both receptors are partially redundant ([@bib27]). However, in line with our data, distinct ROR1 expression was reported in the presumptive cardiac PS region in birds and mammals ([@bib3], [@bib34], [@bib51]) and in embryonic heart tissue as well ([@bib33]). This distinct pattern may hint toward a broader functional role of ROR1 during early heart development, potentially involving non-canonical WNT signaling via FZD4 during lateral plate mesoderm formation ([@bib23], [@bib65]). In summary, we show that ROR1 may be exploited to identify primed hPSC states and predict lineage commitment, complementing recent findings on cKIT, FZD4, and GARP ([@bib5], [@bib40], [@bib65]).

A number of recently published studies progress toward the mass production of hPSC-CMs in stirred suspension culture ([@bib10], [@bib19]). In notable accordance, we confirm the role of preculture duration; 2 days of aggregation in E8 was optimally equivalent in our setup to Chen et al., whereas Fonoudi et al. favored prolonged cultivation for 5 days ([@bib10], [@bib19]). However, both studies suggested that the time-dependent increase in aggregate diameter, rather than preculture duration itself, is a predominant factor. Our previous studies also indicate that the hPSC aggregate diameter and, in particular, the process-dependent pattern of aggregate formation and growth, is important ([@bib31], [@bib29]). However, whereas Chen et al. and Fonoudi et al. in unison support a median hPSC aggregate diameter of ∼175--220 μm as being optimal, we here found a median diameter of ∼125 μm (preculture day 2) being advantageous for cardiomyogenesis as compared with ∼200 μm (on day 4 or preculture; [Figures 3](#fig3){ref-type="fig"}B--3F). This comparison of different studies highlights that probably none of these process parameters (such as preculture duration, aggregate diameter, and inoculation cell density) represents an absolute requirement or a universal process-independent parameter for controlling directed lineage differentiation. These are rather correlative observations, which have to be interpreted within the context of the respective process. Interestingly, the group of Oh recently investigated the proliferative status of hPSCs regarding their impact on the cardiac differentiation efficiency ([@bib36]). Results suggest that monitoring defined molecular markers of cell proliferation may indeed be a more universal, culture platform-independent approach to preassess hPSCs\' compatibility with cardiac differentiation, although additional validation is required.

Regarding process yields, [@bib10] published ∼0.2 million CMs/mL whereas [@bib19] reported ∼0.8 million CMs/mL in their approach ([@bib10], [@bib19]). We here show the induction of ∼1 million CMs/mL in process dimensions from 150 to 500 mL across two bioreactor platforms at increasing dimension, ultimately resulting in the production of up to ∼450 × 10^6^ CMs in a single process run. Using a non-directed differentiation approach followed by antibiotic selection, [@bib13] reported the production of 2.3 × 10^6^ CMs/mL in WAVE bioreactors compared with 0.64 × 10^6^ in stirred tank bioreactors ([@bib13]). In another concept applying microcarriers, [@bib59] generated up to 1.6 × 10^6^ CMs/mL. A meaningful cross-comparison of these studies is problematic, given the great heterogeneity of bioreactor platforms and the overall experimental environment. Importantly, our protocol described here is one of the first demonstrating chemically defined conditions in scalable suspension culture inducing a high CM content of \>90%.

Notably, functional characterization by numerous complementary methods revealed a predominantly ventricular-like CMs phenotype, which may support *in vitro* disease modeling and pharmacological assays as well as envisioned regenerative therapies of heart repair ([@bib39]).

Experimental Procedures {#sec4}
=======================

For standard methods and prepublished techniques, please refer to [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Cell Culture {#sec4.1}
------------

The cell lines HES3 (HES3-MIXL1^wt/eGFP^; [@bib14], HES3-NKX2.5^wt/eGFP^; [@bib16]), H9, HSC_iPS2 (hHSC_F1285_T-iPS2; [MHHi006-A](https://hpscreg.eu/cell-line/MHHi006-A){#intref0010}; [@bib26]), Phoenix (HSC_ADCF_SeV-iPS2; [MHHi001-A](https://hpscreg.eu/cell-line/MHHi001-A){#intref0015}; [@bib24], [@bib30]), CBiPS2 (hCBiPS2; [@bib25]), bMHC_iPS (hF_HCMR723G_4F_iPS_Klon2_MOI1), SFC840 (SFC840-03-01, [STBCi026-B](https://hpscreg.eu/cell-line/STBCi026-B){#intref0020}; [@bib11]; derived by the StemBANCC initiative <http://stembancc.org/>), HDFiPS (HDF-iPSC; [@bib62]), and CDX2_iPS (CDX2^Venus^ knockin reporter, [MHHi007-A-1](https://hpscreg.eu/cell-line/MHHi007-A-1){#intref0030}; [@bib42]) were maintained in mTeSR (STEMCELL Technologies) or E8 medium as described previously ([@bib29]). In brief, cells were passaged every 3.5 days using Accutase (Life Technologies) and reseeded at 0.4--0.5 × 10^4^ cells/mL on Geltrex-coated (Life Technologies) flasks in mTeSR1 (STEMCELL Technologies) or E8 medium including 10 μM Y-27632 (LU Hannover; [@bib50]). Cells were maintained at 37°C and 5% CO~2~ and were regularly tested for mycoplasma contamination using the MycoAlert Mycoplasma Detection Kit (Lonza).

Differentiation was conducted as illustrated in [Figure 1](#fig1){ref-type="fig"}A and as previously described ([@bib31]). At chemically defined conditions, cells were cultivated in E8 and differentiated in CDM3 ([@bib7]; for details see [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}).

Bioreactor Differentiation in Chemically Defined Conditions {#sec4.2}
-----------------------------------------------------------

Chemically defined differentiation in Erlenmeyer flasks (20 mL working volume) and in stirred tank bioreactors (working volume: 150 mL/DASbox Mini Bioreactor System or 350--500 mL/Bioblock DASGIP Parallel Bioreactor System) was performed as depicted in [Figures 3](#fig3){ref-type="fig"}A and [5](#fig5){ref-type="fig"}A, respectively (Eppendorf). After established inoculation/preculture ([@bib35]) cell density was determined after 48 h and adjusted to 5 × 10^5^ cells/mL for differentiation in CDM3 ([@bib7]) supplemented with 5 μM CHIR and 5 μM Y-27632. Precisely 24 h later the medium was replaced by CDM3 plus 5 μM IWP2, and pure CDM3 was added 48 h later and every 2--3 days thereafter. Aggregate diameter, cell density, and metabolites were analyzed as previously published ([@bib35]).

Statistics {#sec4.3}
----------

Data are presented as mean ± standard error of the mean. Unless otherwise noted, statistical significance was calculated using Student\'s t tests. To take account of multiplicity in group comparisons, one- or two-way ANOVA followed by Bonferroni\'s post test were conducted. Statistical significance is denoted by ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, and ns (not significant) in the figures.
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